Allogeneic and autologous, plainly

These two words do more work than any others in this field, and they are usually introduced somewhere around paragraph nine of an explanation that assumed you already knew them. They are simple.

Autologous means it came from you. Allogeneic means it came from somebody else.

Why one distinction carries so much

Almost everything downstream follows from it. If material came from the patient, there is no donor to screen, no serology to run, no traceability chain reaching back to another human being, and no question of immune mismatch. There is instead a draw, a preparation step, staff time on the day, and a yield that varies with the person in the chair.

If it came from a donor, none of that applies and an entirely different apparatus does: donor screening, infectious-disease testing, processing windows, sterility testing, lot records, and paperwork that has to travel with every unit. That apparatus is not bureaucracy for its own sake. It is the only thing standing between a recipient and a donor's undetected infection.

Where each one usually shows up

• Autologous: platelet-rich plasma, bone marrow concentrate, adipose-derived preparations — anything drawn and processed from the patient, usually within the same appointment.
• Allogeneic: perinatal-derived material such as Wharton's jelly, amniotic products, and donor-derived extracellular vesicles.

The question each one invites

For autologous material, the useful question is about process: what device, what spin protocol, what was actually concentrated, and how much variation there is between patients. Two clinics can run the same-sounding procedure and produce meaningfully different preparations.

For allogeneic material, the useful question is about provenance: where did this come from, who screened the donor, what was the processing standard, what testing did this lot pass, and may I see the certificate for the unit in front of me rather than a specimen document.

What neither word tells you

Whether it works. Neither is inherently better and neither is inherently safer; they carry different risks and answer different questions. Anyone who tells you allogeneic is more potent, or that autologous is safer because it is yours, has skipped from a fact about origin to a claim about outcome, and those are separate arguments requiring separate evidence.

Nothing in this category, from either side of the line, is FDA approved for the prevention, treatment, mitigation or cure of any disease. What differs is what can be documented, and that is worth understanding before anybody quotes you a price.